2seventy bio Reiterates Commitment to Maximizing Shareholder Value

CAMBRIDGE, Mass.--()--2seventy bio, Inc. (NASDAQ: TSVT), (“2seventy” or “the Company”), a leading immuno-oncology cell therapy company, today issued the following statement reiterating its commitment to maximizing shareholder value:

As we indicated last month, the Board has commenced a process to consider all options to maximize value. This process is well underway and our team is committed to working as thoughtfully and quickly as possible to ensure our important therapies become available to patients in need, we drive value for our shareholders and best support our employees.

About 2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape.

With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: X (Twitter) and LinkedIn.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of applicable laws and regulations. These statements include, but are not limited to, statements concerning our process to consider all options to maximize value. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, our ability to successfully execute on our evaluation of value-maximizing options and on any resulting strategic or other related actions. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2022 and our quarterly report on Form 10-Q for the quarter ended September 30, 2023, as supplemented and/or modified by our most recent Quarterly Report on Form 10-Q and any other filings that we have made or will make with the Securities and Exchange Commission in the future. All information in this press release is as of the date of the release, and 2seventy bio undertakes no duty to update this information unless required by law.

Contacts

Investors:
Elizabeth Pingpank Hickin, 860-463-0469
Elizabeth.pingpank@2seventybio.com

Media:
Jenn Snyder, 617-448-0281
Jenn.snyder@2seventybio.com

Morgan Adams Shields, 774-313-9852
morgan.adams@2seventybio.com

Contacts

Investors:
Elizabeth Pingpank Hickin, 860-463-0469
Elizabeth.pingpank@2seventybio.com

Media:
Jenn Snyder, 617-448-0281
Jenn.snyder@2seventybio.com

Morgan Adams Shields, 774-313-9852
morgan.adams@2seventybio.com